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shown to protect against N nitrosobis(2 oxopropyl)amine induced
pancreatic tumors in hamster [32]. In some in vitro experiments,
nimesulide is able to inhibit the proliferation and to increase the
apoptosis rate of various types of cancer cells [18,25,33e38].
However, the nimesulide concentrations used in these studies are
ranged from 200 to 500 mM, which greatly exceed the concentra
tion necessary to inhibit COX 2 activity. These facts suggest that
nimesulide inhibits cancer cell growth and induces cancer cell
apoptosis independent of COX 2.
JCC76 is a non COX 2 active nimesulide analog (Fig. 1) [39e41],
and it inhibits SKBR 3 breast cancer cell growth with an IC50 of
1.38 mM, which is about 100 fold more active than nimesulide
(Table 1). The N Methylation of JCC76 blocks the ionization of the
sulfonamide group, which abolishes the potential COX 2 activity
[42e44]. In addition, the aromatic nitro group is converted to an
amide moiety on the structure of JCC76, which could diminish the
potential hepatotoxicity, since nimesulide shows hepatotoxicity
due to the multistep nitroreductive bioactivation that produces the
hazardous nitroanion radical and nitroso intermediate [45]. Based
on the structure of JCC76, more analogs were designed and
synthesized in the current studies. Some new analogs such as
CSUOH0901 (NSC751382) inhibited SKBR 3 breast cancer cell
growth with IC50s around 0.1 mMe0.2 mM, which is about 10 fold
more active than JCC76 and almost 1000 fold more active than
nimesulide. In addition, CSUOH0901 inhibited the growth of
a broad range of cancer cell lines with IC50s of 0.2 mM to 0.5 mM. It
also inhibited the growth of HT29 colorectal xenograft in nudemice
as well. All the studies suggest that the newly developed JCC76
derivatives are promising anti cancer drug candidates.
Results and discussion
Compound design and parallel synthesis of JCC76 derivatives
In previous studies, systematic modiﬁcation was performed on
the structure of nimesulide to improve the anti cancer activity and
erase the COX 2 inhibitory activity [41,46]. SAR result suggests that
the dimethyl benzyl and methylsulfonamide moieties are critical
for the nimesulide analogs to inhibit cancer cell growth (Fig. 1).
Further, the conversion of the nitro group to a bulky amide moiety
generated novel anti cancer agent JCC76 [39e41,46]. In the current
study, dimethyl benzyl and methylsulfonamide groups which are
important for the anti cancer activity of the derivatives were
maintained, and we focused on the modiﬁcation of the amide
moiety of JCC76. Various chemical structures including alkyl amide
groups, electron donating or withdrawing group substituted ben
zamides, bulky or small group substituted benzamides, and
heterocyclic amides were introduced at this moiety.
The synthesis is described in Scheme 1. The starting material 2
amino 5 nitrophenol was reﬂuxed with K2CO3 and 2, 5 dimethyl
benzyl chloride to obtain compound a. Sodium hydride and
methanesulfonyl chloride were added to compound a in dry
dimethylformamide (DMF) at room temperature and the reaction
mixture was stirred at room temperature overnight to obtain the
N,N bimethanesulfonamido b. Compound b was hydrolyzed with
10% NaOH solution to generate c as a monomethanesulfonamido
compound. Compound c was treated with sodium hydride and
methyl iodine in DMF at room temperature to obtain compound d.
Then the nitro group was reduced to an amine group to obtain
compound e. Compound e was treated with different substituted
acetyl chloride and K2CO3 to generate the substituted benzamides
1e39, respectively. Structures of all the synthesized compounds
were determined by 1H NMR, MS, and their purity was conﬁrmed
by HPLC with two mobile phases.
Biological evaluation of the new analogs with breast cancer cell
line SKBR 3
The compounds were tested for the inhibition of SKBR 3 breast
cancer cell growth (Table 1). Subsequently, a detailed structure
activity analysis was performed based on the structure and the
anti cancer activity. The new derivatives have same core structure
as JCC76, the different activity is correlatedwith the different amide
moieties.
For the substituted benzamide moiety in the structure, para
position bulky halogen substituted benzamide such as 9 (bromine)
with an IC50 of 0.22 mM and 29 (iodine) with an IC50 of 0.13 mM
show better potency than JCC76, whereas small halogen chlorine at
para position (28) slightly decreases the activity with an IC50 of
2.15 mM. It is also possible that the activity is related to the elec
tronegativity or electron density of the halogens. Iodine has the
lowest electronegativity and highest electron density, which may
contribute to the potent anti cancer activity. 2, 8, 25, 20, and 27,
which have single meta substitution groups, display weaker
inhibitory activity with IC50s ranging from 1.97 mM to 7.34 mM. It
seems that single meta substitution is predominated by steric
effect. The activity is decreased no matter the substitution is
electron donating or withdrawing group. Dual chlorine substitu
tion (4 and 14) slightly increases the activity compared to JCC76,
with IC50 of 0.91 mM and 0.80 mM respectively.1, 2, 3, 7, 8,15, 21 and
34, which have electron withdrawing groups as substitution,
exhibit IC50s among 1.0 mMe3.0 mM. The results suggest that
electron withdrawing groups such as nitro, cynao, multi ﬂuoro,
and triﬂuoro methyl substituted benzamide do not increase the
activity. 26 shows very weaker activity with an IC50 of 55.35 mM,
which possibly is due to the very strong electron withdrawing
effect and the meta position steric effect of the di triﬂuoro
methyl groups. Most of the strong electron donating groups such
as methoxyl and multi methoxyl substituted benzamide (10, 11, 16,
18 and 19) increase the activity with IC50s among 0.19 mMe0.68 mM.
However, para methyl benzamide (33) and para ethyl benzamide
(36) show lesser potency with IC50s of 2.48 mM and 2.82 mM
respectively, although both methyl and ethyl groups are electron
donating substitution. It suggests that para position steric effect
reduces the activity, but strong electron donating group at para
position overall increase the activity because the electron donating
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Fig. 1. Anti-cancer drug development based on COX-2 inhibitor nimesulide.
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Table 1
Inhibition of cancer cell growth of the JCC76 anlogs.
Entry
O
N
S OO
N
H
R
IC50 against
SKBR-3 breast
cancer cell growth
JCC76 R=
O
1.38  0.10 mM
1 R =
O
NO2
1.13  0.10 mM
2 R =
O
NO2 1.97  0.21 mM
3 R =
O
NO2
Cl
3.35  0.40 mM
4 R =
O
Cl
Cl
0.91  0.05 mM
5 R =
O
0.21  0.01 mM
6
R =
O
2.28  0.09 mM
7 R =
O
CN
1.46  0.06 mM
8 R =
O
CN 3.01  0.12 mM
9 R =
O
Br
0.22  0.01 mM
10 (CSUOH0901;
NSC751382)
R =
O
O
O 0.20  0.01 mM
11
R =
O
OCH3
OCH3
OCH3
0.30  0.02 mM
12 R =
O
43.27  7.38 mM
13 R =
O
14
11.05  4.76 m3M
14
R =
O
ClCl
0.80  0.01 mM
Table 1 (continued )
Entry
O
N
S OO
N
H
R
IC50 against
SKBR-3 breast
cancer cell growth
15 R =
O
CF3 2.78  0.29 mM
16 R =
O
OCH3
OCH3
0.19  0.14 mM
17 R =
OCH3
OCH3
O
34.02  2.01 mM
18 R =
O
OCH3
0.15  0.05 mM
19 R =
O OCH3
0.68  0.32 mM
20 R =
O
OCH3 6.88  3.18 mM
21
R =
O
OCH3
F
F
F
2.16  1.08 mM
22 R =
O
51.24  4.49 mM
23 R =
O
11.21  4.47 mM
24 R =
O
>100 mM
25
R =
O
3.95  2.09 mM
26
R =
O
CF3
CF3
55.35  4.11 mM
27 R =
O
Br 7.34  3.99 mM
28 R =
O
Cl
2.15  0.94 mM
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effect overcomes the steric effect. 2 Naphthyl amide (5) increases
the activity with an IC50 of 0.21 mM, but 1 Naphthyl amide (25)
decreases the activity with an IC50 of 3.95 mM. Because 2 Naphthyl
group is more like a dual para and meta position substituted ben
zamide, and the substitution has very strong electron donating
effect at para position due to the super conjugation effect. 1
Naphthyl group is more like a dual meta and ortho position
substituted benzamide, which decreases the activity due to steric
effect of meta substitution. 6 (para phenyl benzamide) shows
weaker activity with an IC50 of 2.28 mM. Because the phenyl group
cannot form super conjugation with the benzamide due to the
steric effect of the two phenyl rings. It makes the phenyl substi
tution predominated mainly by steric effect. Substituted Benzyla
mide, namely 17 and 24, display much weaker activity with IC50s
above 30 mM. Heterocyclic amides (37, 38, 39) decrease the activity,
with IC50s of 16.65 mM, 20.12 mM, and 21.88 mM respectively. The
results suggest that benzamide moiety is better for the activity
compared to the heterocyclic amides.
For the alkyl substituted amide, lead compound JCC76 is still the
most potent one with an IC50 of 1.38 mM. Small alkyl groups such as
ethyl (12), 3 pentyl (22), and cyclopentyl (23) greatly decrease the
activity, and the corresponding IC50 are 43.27 mM, 51.24 mM, and
11.21 mM respectively. Very bulky alkyl group such as hexadacanyl
(13) decreases theactivityaswell,withan IC50 of 11.05mM. It appears
that the best alkyl substitution is a middle size and closed ring.
Overall, para position of the benzamide is very critical for the
anti cancer activity of the JCC76 analogs. Strong electron donating
groups at para position signiﬁcantly increase the activity. Single
meta substituted benzamide greatly decreases the activity, no
matter it is electron donatingorwithdrawing groupas substitution.
Severalverypotent analogs (5,9,10,16,18,29),whichareabout5e10
fold more active than JCC76, share some structure similarity: para
position substituted benzamide, or para and meta both electron
donating group substituted benzamide. 10, discovered earlier in
the study, was named CSUOH0901 and submitted to the Develop
mental Therapeutic Program at the National Cancer Institute for
screening against 60 human tumor cell lines. Itwas also investigated
for the anti cancer mechanism and in vivo activity in the study.
CSUOH0901 caused cell population concentrated at sub G1
and G2 phase
Compound CSUOH0901 signiﬁcantly inhibited SKBR 3 breast
cancer cell growth. It is important to elucidate the anti cancer
mechanisms of the compound. When SKBR 3 cells were treated
with 0.5 mMand 5 mMof CSUOH0901, cells were accumulated at G2/
M and subG1 phase after 12 h. As for 0.25 mM treatment, this
phenomenon was observed after 24 h (Table 2). The results
demonstrate that CSUOH0901 was able to inhibit cell mitosis and
induce cell apoptosis at similar dosage to inhibit cell growth. JCC76
has been shown in previous studies to induce cell apoptosis via
cytochromec release [39,40]. It is not surprising that themorepotent
JCC76 analog CSUOH0901 exhibits better potency to induce cell
apoptosis. However, JCC76 did not show good potency to cause cell
cycle arrest in previous studies [39,40]. CSUOH0901 obviously
exhibited the cell G2/M phase arresting activity. Therefore, the anti
mitosis potency is signiﬁcantly increased by the structure modiﬁ
cation. 0.1 mM CSUOH0901 clearly induced subG1 cell accumulation
after 24 h treatment, but no G2/M cell accumulation was observed,
suggesting that the compound at low concentrations was able to
induce cell apoptosis without affecting the cell replication. It is
difﬁcult to determine if the cell apoptosis and cell growth arrested by
the compound are correlated or not, since the speciﬁc molecular
targets of CSUOH0901 still remain unclear. Further investigation is
needed to identify the anti cancer molecular targets of these
compounds.
Multi cancer cell lines growth inhibition and animal acute
toxicity studies of CSUOH0901
Due to the structure novelty and potency of CSUOH0901, it was
submitted to theDevelopmental Therapeutic Programat theNational
Cancer Institute (assignedwithcodeNSC751382), andwasselectedby
Table 1 (continued )
Entry
O
N
S OO
N
H
R
IC50 against
SKBR-3 breast
cancer cell growth
29 R =
O
I
0.13  0.07 mM
30 R =
O
SCH3
0.66  0.32 mM
31
R =
O
N
1.01  0.52 mM
32 R =
O
OC2H5
0.41  0.03 mM
33 R =
O
C2H5
2.48  1.44 mM
34 R =
O
CF3
1.20  0.59 mM
35 R =
O
OCF3
0.58  0.29 mM
36 R =
O
CH3
2.82  1.51 mM
37 R =
O
O 16.65  2.26 mM
38 R =
O
S 20.12  5.28 mM
39 R =
O
NO 21.88  5.08 mM
Cells were treated with indicated compounds at various concentrations by six
replicates for 48 h and cell viability was measured by MTT assay as described in the
experimental section.
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1,4-dioxane
Acyl chloride
O
N
H
N
S OO
O
R
1 R= 4-Nitro-phenyl (88%)
2 R= 3-Nitro-phenyl (86%)
3 R= 4-Chloro-3-nitro-phenyl (82%)
4 R= 3,4-Dichloro-phenyl (69%)
5 R= 2-Naphthyl (72%)
6 R= 4-Biphenyl (73%)
7 R= 4-Cyano-phenyl (75%)
8 R= 3-Cyano-phenyl (71%)
9 R= 4-Bromo-phenyl (80%)
10 R= 5-Benzo[1,3]dioxolyl(71%)
11 R= 3,4,5-Trimethoxy-phenyl (93%)
12 R= Propionyl (88%)
13 R= Hexadecanyl (98%)
14 R= 2,4-Dichloro-phenyl (80%)
15 R= 3-Trifluoromethyl-phenyl (93%)
16 R= 3,4-Dimethoxy-phenyl (93%)
17 R= 3,4-Dimethoxy-benzyl (95%)
18 R= 4-Methoxy-phenyl (96%)
19 R= 2-Methoxy-phenyl (97%)
O2N OH
NH2
K2CO3, DMF
2, 5-dimethyl
Benzyl Chloride
O2N
NH2
O NaH, DMF
CH3SO2Cl
O2N
NH
O
SO O
NaH, DMF, CH3I O2N
N
O
SO O
Zn/FeCl3/H2O/DMF
H2N
N
O
SO O
a
O2N
N
O
SO O
S
O
O
b
c
d
e
20 R= 3-Methoxy-phenyl (91%)
21 R= 3-Methoxy-2,4,5-trifluorophenyl (98%)
22 R= 3-Pentyl (96%)
23 R= Cyclopentyl (93%)
24 R= Benzyl (99%)
25 R= 1-Naphthyl (83%)
26 R= 3,5-Bis(trifluoromethyl)-phenyl (93%)
27 R= 3-Bromophenyl (99%)
28 R= 4-Chlorophenyl (99%)
29 R= 4-Iodophenyl (96%)
30 R= 4-Methylsulfanyl-phenyl (92%)
31 R= 4- Dimethylamino-phenyl (66%)
32 R= 4-Ethoxy-phenyl (70%)
33 R= 4-Ethyl-phenyl (64%)
34 R= 4-Trifluoromethyl-phenyl (84%)
35 R= 4-Trifluoromethoxy-phenyl(79%)
36 R= 4-Methyl-phenyl (69%)
37 R= 2-Furyl (66%)
38 R= 2-Thiophenyl (72%)
39 R= 5-Isoxazolyl(99%)
aq NaOH
Scheme 1. Synthesis of JCC76 analogs.
Table 2
Summary of altered cell cycle distribution in response to treatment with CSUOH0901 (NSC751382). SKBR-3 cells were treated for different time period with the indicated
concentrations of compound. Cells were processed for FACS using propidium iodide staining as described. Percent distribution of cells in each cell cycle phase was displayed.
Time Concentrations
of CSUOH0901
Sub-G1% G1% S% G2/M%
3 h 0.10 (mM) 3.12 70.84 17.20 8.83
0.25 (mM) 3.23 69.63 16.34 10.77
0.50 (mM) 3.43 67.14 17.76 11.54
5.0 (mM) 2.81 69.09 16.49 11.57
6 h 0.10 (mM) 3.60 71.43 15.84 9.07
0.25 (mM) 3.49 72.21 14.95 9.32
0.50 (mM) 4.03 67.10 14.73 13.90
5.0 (mM) 3.42 64.76 14.61 17.19
12 h 0.10 (mM) 5.27 73.14 8.17 12.05
0.25 (mM) 6.85 73.62 6.14 13.35
0.50 (mM) 6.36 63.15 5.94 24.26
5.0 (mM) 9.76 63.71 5.99 20.54
18 h 0.10 (mM) 6.04 75.43 8.71 9.71
0.25 (mM) 8.89 73.42 6.81 10.57
0.50 (mM) 8.47 61.19 7.28 22.27
5.0 (mM) 8.31 63.55 6.73 21.80
24 h 0.10 (mM) 11.78 67.90 8.91 11.23
0.25 (mM) 24.95 41.27 10.87 22.53
0.50 (mM) 27.94 31.77 11.21 28.14
5.0 (mM) 27.62 31.87 11.53 28.29
436
NCIDTP for screening against 60human tumor cell lines, representing
leukemia,melanoma, andcancersof the lung, colon,CNS, ovary, renal,
prostate, and breast. After 48 h treatment, CSUOH0901 does depen
dently inhibited the growthof sixty cell lines fromeachclass of tumor
cells. Three dose response parameters are calculated for the experi
mental agent. Growth inhibition of 50% (GI50) is the drug concen
tration resulting in a 50% reduction in the net protein increase
comparedwith control cells during the drug incubation. Total growth
inhibition (TGI) shows the drug concentration that causes a 100%
reduction in the net protein increase during the drug incubation. The
LC50 is the concentration of drug resulting in a 50% reduction in
protein at the end of the drug treatment as compared to the protein
amount present at the time of drug addition. Values are calculated for
each of these three parameters if the requisite level of activity is
achieved. The values of these parameters among the 60 different cell
lines after 48 h treatment are as follows: concentration resulting in
50% growth inhibition (GI50), 0.03 mMe0.5 mM; concentration
resulting in total growth inhibition (TGI), 0.2 mMe2.0 mM (in
approximately one half of the cell lines); concentrations resulting in
a 50% reduction in the measured protein level at the end of drug
treatment (LC50), above 20 mM in only 3 cell lines (Table 3).
The compound was also tested for the acute toxicity to deter
mine themaximum tolerated dose in nudemice. After a single dose
of 400 mg/kg, 200 mg/kg, or 100 mg/kg, the nude mice were
observed for a period of 2 weeks. No body weight lost was found in
the three mice tested, indicating that the animals were highly
tolerable to CSUOH0901.
In vivo investigation
To determinewhether the high activity of our compounds at cell
culture would be translated into in vivo active anti cancer agents,
CSUOH0901 as a representative one was investigated in the tumor
xenograft nude mice model. SKBR 3 cells do not readily form
xenografts in nude mice, therefore we used a colon cancer HT29
xenograft model to investigate the in vivo activity of the compound,
since it signiﬁcantly inhibited HT29 cell growth in the in vitro study
(Developmental Therapeutics Program at National Cancer Institute)
with an IC50 of 0.42 mM (Table 3). We conﬁrmed the activity of
CSUOH0901 in HT29 cells with an MTT cell proliferation assay, and
obtained an IC50 of 0.46 mM. HT29 xenograft is a well established
in vivo tumor model, and has been used to test the activity of many
anti cancer drug candidates. Nude mice (three mice per group, two
tumors per mouse) bearing HT29 xenografts were given daily (5
times perweek) intraperitoneal injections (5mg/kg) of CSUOH0901
for three weeks after the tumor reached a measurable size.
CSUOH0901 treatment signiﬁcantly decreased the size of the
HT29 tumors compared to the control group (Fig. 2A). Weights of
the mice were not affected by the treatment (Fig. 2B), suggesting
the low toxicity of the compound. After the treatment, the tumors
were removed and weighed. CSUOH0901 signiﬁcantly decreased
the tumor weights as well (Fig. 2C). The results reveal that
CSUOH0901 is active in vivo and could be a promising anti cancer
drug candidate.
Pharmacokinetic study
CSUOH0901 exhibited potent in vitro and in vivo anti tumor
activity. To support future further pharmacological and toxicolog
ical study, a pharmacokinetic study of the compound was also
performed. CSUOH0901was administrated to rats intraperitoneally
at a dose of 20 mg/kg. Blood samples (150 mL each) were collected
from the saphenous veins and femoral veins into heparized tubes at
0 h (before drug administration) and at 0.25, 0.5, 1, 2, 4, 8 and 24 h
after dosing. The peripheral blood drug level was then determined
Table 3
Growth inhibitory effect of CSUOH0901 on 60 human tumor cell lines. Growth
inhibition of 50% (GI50), total growth inhibition (TGI), and LC50 are listed in the
table.
Panel/Cell line GI50 TGI LC50
Leukemia
CCRF-CEM 4.85E-8 >1.00E-4 >1.00E-4
HL-60(TB) 2.69E-8 9.67E-8 >1.00E-4
K-562 4.03E-8 >1.00E-4 >1.00E-4
MOLT-4 1.63E-7 >1.00E-4 >1.00E-4
RPMI-8226 2.90E-7 >1.00E-4
Non-small cell lung cancer
A549/ATCC 2.78E-7 1.36E-5 >1.00E-4
EKVX 5.98E-7 > 1.00E-4 >1.00E-4
HOP-62 3.29E-7 > 1.00E-4 >1.00E-4
HOP-92 3.22E-6 > 1.00E-4 >1.00E-4
NCI-H226 6.86E-7 > 1.00E-4 >1.00E-4
NCI-H23 1.62E-7 > 1.00E-4 >1.00E-4
NCI-H322M 4.68E-7 > 1.00E-4 >1.00E-4
NCI-H460 1.84E-7 7.44E-7 >1.00E-4
NCI-H522 3.35E-8 2.40E-7 >1.00E-4
Colon cancer
COLO 205 3.18E-7 1.07E-6 >1.00E-4
HCC-2998 1.20E-7 3.92E-7 2.97E-6
HCT-116 7.53E-8 1.02E-6 >1.00E-4
HCT-15 2.89E-7 >1.00E-4 >1.00E-4
HT29 7.72E-8 4.19E-7 >1.00E-4
KM12 8.55E-8 1.13E-6 >1.00E-4
SW-620 1.12E-7 >1.00E-4 >1.00E-4
CNS cancer
SF-268 2.88E-7 >1.00E-4 >1.00E-4
SF295 9.83E-8 6.26E-7 >1.00E-4
SF539 1.25E-7 >1.00E-4
SNB-19 5.37E-7 >1.00E-4 >1.00E-4
SNB-75 2.66E-7 >1.00E-4
U251 2.66E-7 2.19E-5 >1.00E-4
Melanoma
LOXIMVI 6.66E-8 >1.00E-4 >1.00E-4
MALME-3M 2.29E-7 >1.00E-4 >1.00E-4
M14 7.57E-8 6.69E-7 >1.00E-4
MDA-MB-435 2.85E-8 9.14E-8 >1.00E-4
SK-MEL-2 8.97E-8 6.16E-7 >1.00E-4
SK-MEL-28 6.92E-7 >1.00E-4 >1.00E-4
SK-MEL-5 2.53E-7 1.65E-6 3.41E-5
UACC-257 1.44E-7 >1.00E-4 >1.00E-4
UACC-62 4.14E-7 >1.00E-4 >1.00E-4
Ovarian cancer
IGROV1 2.37E-7 >1.00E-4 >1.00E-4
OVCAR-3 3.96E-8 1.66E-7
OVCAR-4 >1.00E-4 >1.00E-4
OVCAR-5 5.38E-7 >1.00E-4 >1.00E-4
OVCAR-8 2.65E-7 >1.00E-4 >1.00E-4
NCI/ADR-RES 5.62E-8 4.07E-7 >1.00E-4
SK-OV-3 2.85E-7 >1.00E-4 >1.00E-4
Renal cancer
786 0 1.91E-7 1.11E-6 >1.00E-4
A498 1.22E-7 8.53E-7 >1.00E-4
ACHN 6.87E-7 >1.00E-4 >1.00E-4
CAKI-1 1.26E-7 >1.00E-4 >1.00E-4
RXF 393 1.28E-7 4.03E-7 >1.00E-4
SN12C 4.72E-7 >1.00E-4 >1.00E-4
TK-10 3.54E-7 >1.00E-4 >1.00E-4
UO-31 3.95E-7 >1.00E-4 >1.00E-4
Prostate cancer
PC-3 6.77E-8 >1.00E-4 >1.00E-4
DU-145 1.59E-7 4.57E-7 >1.00E-4
Breast cancer
MCF7 1.20E-7 >1.00E-4 >1.00E-4
MDA-MB-231/ATCC 2.56E-7 9.26E-7 >1.00E-4
HS 578T 8.70E-8 >1.00E-4
BT-549 6.56E-7 >1.00E-4 >1.00E-4
T-47D 6.82E-7 >1.00E-4 >1.00E-4
MDA-MB-468 1.55E-7 4.01E-7 1.99E-5
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with LC MS/MS. The mean CSUOH0901 concentration in plasma
versus time proﬁle was presented in Fig. 3. Peak drug concentra
tions were observed at 2 h after administration and reached
nearly1500 ng/mL. The pharmacokinetic parameters were calcu
lated by using non compartmental model. The estimated phar
macokinetic parameters including the terminal phase elimination
half life (T1/2), the area under the plasma concentration time
curve (AUC) from time 0 to time of the last measurable concen
tration (AUC(0-t)), the volume of distribution (Vz/F), the total body
clearance (Cl/F), and the mean residence time (MRT) from time 0 to
time of the last measurable concentration (MRT(0-t)) are listed in
Table 4. The half life and volume of distribution of the compound is
relatively lower compared with more hydrophobic anti cancer
drugs such as Taxol [47], suggesting the compound has better
drug like characters than Taxol. The good bioavailability of the
compound recommends further drug development of these small
molecule anti cancer agents.
Conclusion
The structural modiﬁcations of nimesulide have been effective
in abolishing its COX 2 inhibiting property and reducing its hepa
totoxicity. Among the new derivatives synthesised, compounds 5,
9, 10 (CSUOH0901), 16, 18 and 29 have exhibited good growth
inhibitory activity against SK BR 3 breast cancer cells at low
nanomolar concentrations. CSUOH0901 displayed good potency
to inhibit the growth of a broad range of cancer cell lines and
demonstrated minor animal toxicity. The in vivo tumor suppression
activity and pharmacokinetic results of CSUOH0901 suggest that
the drug candidate has great clinical application potential.
Experimental section
Chemistry
Chemicals were commercially available and used as received
without further puriﬁcation unless otherwise noted. Moisture
sensitive reactions were carried out under a dry argon atmosphere
in ﬂame dried glassware. Solvents were distilled before use under
argon. Thin layer chromatography was performed on precoated
silica gel F254 plates (Whatman). Silica gel column chromatog
raphy was performed using silica gel 60A (Merck, 230 400 Mesh),
and hexane/ethyl acetate was used as the elusion solvent. Mass
spectra were obtained on the Micromass QTOF Electrospray mass
spectrometer at Cleveland State University MS facility Center.
Melting point was recorded with a Mel Temp melting point appa
ratus. All the NMR spectra were recorded on a Varian 400 MHz in
either DMSO d6 or CDCl3. Chemical shifts (d) for 1H NMR spectra
are reported in parts per million to residual solvent protons. The IR
spectra were obtained on a Bruker ALPHA FT IR spectrometer with
ATR module.
For the HPLC analysis, a 1.00 mg/mL stock solution of each
standard was prepared in either methanol or acetonitrile. The HPLC
system consists of two LC 20AD pumps, a DGU 20A3 degasser,
a SIL 20AC autosampler, and a CBM 20A module (Shimazu, Tokyo,
Japan). The chromatographic separation was performed on a Luna
C18 column (2.0 mm  150 mm, 5 mm) with a guard column
(2 mm  40 mm, 5 mm) from Phenomenex (Torrance, CA, USA) at
room temperature with a ﬂow rate of 0.2 mL/min. Two mobile
phases (10mMammonium acetate in 90%methanol or acetonitrile)
were employed to run 15 min. An injection volume of 5e15 mL was
used. The UV detector was set up at 290 and 256 nM.
Compounds aeewere prepared as described by Su et al. [41,46].
General procedure for the preparation of the substituted
benzamide 1e39
K2CO3 (5mmol, 5eq) and substituted acyl chloride (1.2mmol,1.2
eq) were successively added to a solution of the aniline e (1.0 mmol,
1.0 eq) in 3 mL dry 1, 4 dioxane and the mixture was stirred at
room temperature overnight. 10 mL H2O and 3 mL saturated
aqueous Na2CO3 was added to the mixture and it was stirred at
room temperature overnight. The precipitated solid was collected
by ﬁltration and puriﬁed by silica gel column chromatography.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 nitro benzamide (1). 4 Nitro benzoyl chloride
was used and it was stirred at room temperature overnight. Pale
yellow solid, melting point 206e209 C, yield 88%: 1H NMR
(400 MHz, DMSO d6) d 10.68 (1H, s), 8.41 (2H, d, J 8.0 Hz), 8.21
(2H, d, J 8.2 Hz), 7.75 (1H, s), 7.44 (1H, d, J 8.4 Hz), 7.33(2H, m),
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Fig. 2. In vivo anti-cancer evaluation of CSUOH0901. A. Nude mice bearing HT29
xenograft after the treatment. The treatment group is signiﬁcantly smaller than the
control group (n 6); B Mice weight changing (n 3); C HT29 tumor weight
comparison (n 6). *P < 0.05 vs control.
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7.15(1H, d, J 7.8 Hz), 7.09(1H, d, J 7.8 Hz), 5.11 (2H, s), 3.12 (3H, s),
2.88 (3H, s), 2.32 (3H, s), 2.28 (3H, s); HRMS calculated for
C24H26N2NaO4S [M þ Na]þ 461.1511, found: 461.1511.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 3 nitro benzamide (2). 3 Nitro benzoyl chloride was
used and it was stirred at room temperature overnight. White solid,
melting point 163e165 C, yield 86%: 1H NMR (400 MHz, DMSO d6)
d 10.70 (1H, s), 8.80 (1H, s), 8.48 (1H, d, J 8.0 Hz), 8.43 (1H, d,
J 8.0 Hz),7.89 (1H, dd, J 7.8, 7.8 Hz), 7.75 (1H, s), 7.45 (1H,d,
J 8.6 Hz),7.34(2H, m), 7.15(1H, d, J 7.4 Hz), 7.09 (1H, d, J 7.5 Hz),
5.12 (2H, s), 3.12 (3H, s), 2.88 (3H, s), 2.33 (3H, s), 2.28 (3H, s). ESI MS
(m/z) calculated for C24H24N3O6S [M þ H]þ: 482.1, found: 481.9.
4 Chloro N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl
methyl amino) phenyl] 3 nitro benzamide (3). 4 Chloro 3 nitro be
nzoyl chloride was used and it was stirred at room temperature
overnight. White solid, melting point 204e206 C, yield 82%: 1H
NMR (400 MHz, DMSO d6) d 10.65 (1H, s), 8.65 (1H, s), 8.28 (1H, d,
J 8.4 Hz), 8.01 (1H, d, J 8.4 Hz), 7.72 (1H, s), 7.42 (1H, d,
J 8.4 Hz), 7.33(2H,m), 7.15(1H, d, J 7.7 Hz), 7.09 (1H, d, J 7.4 Hz),
5.11 (2H, s), 3.12 (3H, s), 2.87 (3H, s), 2.32 (3H, s), 2.28 (3H, s). ESI MS
calculated for C24H23ClN3O6S [M þ H]þ: 516.1, found: 515.8.
3,4 Dichloro N [3 (2,5 dimethyl benzyloxy) 4 (methanesulf
onyl methyl amino) phenyl] benzamide (4). 3,4 Dichloro benzoyl
chloride was used and it was stirred at room temperature over
night. White solid, melting point 177e179 C, yield 69%: 1H NMR
(400 MHz, DMSO d6) d 10.51 (1H, s), 8.23 (1H, s), 7.97 (1H, d,
J 8.4 Hz), 7.85 (1H, d, J 8.4 Hz), 7.73 (1H, s), 7.42 (1H, d,
J 7.6 Hz), 7.31(2H, m), 7.15(1H, d, J 7.7 Hz), 7.09 (1H, d,
J 7.6 Hz), 5.10 (2H, s), 3.12 (3H, s), 2.87 (3H, s), 2.32 (3H, s), 2.28
(3H, s). ESI MS calculated for C24H23Cl2N2O4S [M þ H]þ: 505.1,
found: 504.8.
Naphthalene 2 carboxylic acid [3 (2,5 dimethyl benzyloxy) 4
(methanesulfonyl methyl amino) phenyl] amide (5). Naphthalene
2 carbonyl chloridewas used and it was stirred at room temperature
for three days. White solid, melting point 133e136 C, yield 72%: IR
n 3314 (NeH), 1649 (C]O), 1595, 1509 (aromatic C]C). 1H NMR
(400 MHz, DMSO d6) d 10.56 (1H, s), 8.60 (1H, s), 8.12 (4H, m), 7.82
(1H, s), 7.67 (2H, m), 7.50 (1H, d, J 8.5 Hz), 7.33(2H, m), 7.16(1H, d,
J 7.8 Hz), 7.10 (1H, d, J 7.3 Hz), 5.13 (2H, s), 3.13 (3H, s), 2.88 (3H,
s), 2.34 (3H, s), 2.29 (3H, s). 13C NMR (100MHz, DMSO d6) d 165.581,
155.169, 148.112, 140.164, 134.702, 134.229, 134.084, 133.100,
131.925, 130.956, 130.003, 129.133, 128.874, 128.660, 127.989,
127.951, 127.836, 127.600, 126.829, 124.663, 124.297, 112.289,
105.348, 68.106, 37.623, 37.509, 20.520,17.873. ESI MS calculated for
C28H27N2O4S [M þ H]þ: 487.2, found: 486.9.
Biphenyl 4 carboxylic acid [3 (2,5 dimethyl benzyloxy) 4
(methanesulfonyl methyl amino) phenyl] amide (6). Biphenyl 4
carbonyl chloride was used and it was stirred at room tempera
ture for three days. White solid, melting point 136e139 C, yield
73%: 1H NMR (400 MHz, DMSO d6) d 10.42 (1H, s), 8.09 (2H, d,
J 7.9 Hz), 7.88 (2H, d, J 7.8 Hz), 7.81 (1H, s), 7.79 (2H, d,
J 7.2 Hz), 7.54(4H, m), 7.33 (2H, m), 7.16(1H, d, J 7.7 Hz), 7.10 (1H,
d, J 7.5 Hz), 5.12 (2H, s), 3.12 (3H, s), 2.87 (3H, s), 2.33 (3H, s), 2.28
(3H, s). ESI MS calculated for C30H29N2O4S [M þ H]þ: 513.2, found:
512.9.
4 Cyano N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl
methyl amino) phenyl] benzamide (7). 4 Cyano benzoyl chloride
was used and it was stirred at room temperature overnight. White
solid, melting point 183e187 C, yield 75%: 1H NMR (400 MHz,
DMSO d6) d 10.60 (1H, s), 8.13 (2H, d, J 8.4 Hz), 8.06 (2H, d,
J 8.2 Hz), 7.75 (1H, d, J 1.7 Hz), 7.43 (1H, dd, J 1.9, 8.5 Hz), 7.32
(2H, m), 7.15(1H, d, J 7.7 Hz), 7.09 (1H, d, J 7.7 Hz), 5.11 (2H, s),
3.12 (3H, s), 2.87 (3H, s), 2.32 (3H, s), 2.28 (3H, s). ESI MS calculated
for C25H24N3O4S [M þ H]þ: 462.1, found: 461.9.
3 Cyano N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl
methyl amino) phenyl] benzamide (8). 3 Cyano benzoyl chloride
was used and it was stirred at room temperature overnight. White
solid, melting point 166e170 C, yield 71%: 1H NMR (400 MHz,
DMSO d6) d 10.54 (1H, s), 8.42 (1H, s), 8.27 (1H, d, J 7.8 Hz), 8.10
(1H, d, J 7.7 Hz), 7.80 (2H, m), 7.43 (1H, d, J 8.5 Hz), 7.32(2H, m),
7.15(1H, d, J 7.7 Hz), 7.09 (1H, d, J 7.8 Hz), 5.11 (2H, s), 3.12 (3H,
Fig. 3. CSUOH0901 rats blood concentrations vs time. CSUOH0901 was administrated to rats (n 3) intraperitoneally with 20 mg/kg. Blood samples of 150 mL each were collected
from the saphenous veins and femoral veins into heparized tubes at 0 h (before drug administration) and at 0.25, 0.5, 1, 2, 4, 8 and 24 h after dosing. The blood drug concentration
was then determined with LC-MS/MS.
Table 4
The pharmacokinetic parameters of CSUOH0901.
Parameters Rat 1 Rat 2 Rat 3 Mean S.D.
T1/2 (h) 2.44 3.71 3.21 3.12 0.64
AUC(0 t) (ng*h/mL) 16466 22648 9718 16277 6467
Vz/F (L/kg) 1.51 1.65 3.33 2.16 1.01
Cl/F (L/h) 0.42 0.32 0.70 0.48 0.20
MRT(0 t) (h) 5.95 6.43 5.62 6.00 0.40
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s), 2.87 (3H, s), 2.32 (3H, s), 2.28 (3H, s). ESI MS calculated for
C25H24N3O4S [M þ H]þ: 462.1, found: 461.9.
4 Bromo N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl
methyl amino) phenyl] benzamide (9). 4 Bromo benzoyl chloride
was used and it was stirred at room temperature overnight. White
solid, melting point 196e197 C, yield 80%: IR n 3338 (NeH), 1654
(C]O), 1593, 1507 (aromatic C]C). 1H NMR (400 MHz, DMSO d6)
d 10.43 (1H, s), 7.93 (2H, d, J 8.2 Hz), 7.79 (2H, d, J 8.5 Hz), 7.75
(1H, s), 7.40 (1H, m), 7.31 (2H, m), 7.15(1H, d, J 7.7 Hz), 7.09 (1H, d,
J 7.7 Hz), 5.10 (2H, s), 3.11 (3H, s), 2.87 (3H, s), 2.32 (3H, s), 2.28
(3H, s). 13C NMR (100 MHz, DMSO d6) d 164.551, 155.146, 139.874,
134.702, 134.046, 133.657, 133.100, 131.368, 130.948, 130.003,
129.720,129.141,128.668,125.456,124.815,112.335,105.393, 68.114,
37.623, 37.486, 20.520, 17.866. ESI MS calculated for C24H24BrN2O4S
[M þ H]þ: 515.1, found: 514.8.
Benzo[1,3]dioxole 5 carboxylic acid [3 (2,5 dimethyl ben
zyloxy) 4 (methanesulfonyl methyl amino) phenyl] amide (10). 1,3
Dihydro isobenzofuran 5 carbonyl chloride was used and it was
stirred at room temperature overnight. White solid, melting point
159e165 C (decomposed), yield 71%: IR n 3354 (NeH), 1653 (C]
O), 1596, 1506 (aromatic C]C). 1H NMR (400 MHz, DMSO d6)
d 10.18 (1H, s), 7.75 (1H, s), 7.60 (1H, d, J 8.1 Hz), 7.52 (1H, s), 7.41
(1H, dd, J 1.5, 8.4 Hz), 7.31 (1H, s), 7.28 (1H, d, J 8.5 Hz), 7.15(1H,
d, J 7.6 Hz), 7.09 (2H, d, J 8.0 Hz), 6.15 (2H, s), 5.09 (2H, s), 3.11
(3H, s), 2.86 (3H, s), 2.32 (3H, s), 2.28 (3H, s). 13C NMR (100 MHz,
DMSO d6) d 164.475, 155.100, 150.088, 147.311, 140.186, 134.686,
134.068, 133.107, 130.857, 129.995, 129.171, 128.660, 128.362,
124.472, 122.832, 112.206, 107.873, 107.598, 105.271, 101.770,
68.076, 37.585, 37.493, 20.513, 17.858. ESI MS calculated for
C25H25N2O6S [M þ H]þ: 481.1, found: 480.8.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 3,4,5 trimethoxy benzamide (11). 3,4,5 Trimethoxy
benzoyl chloride was used and it was stirred at room temperature
overnight. White solid, melting point 187e189 C, yield 93%: 1H
NMR (400 MHz, DMSO d6) d 10.26 (1H, s), 7.76 (1H, s), 7.36 (5H, m),
7.13(1H, d, J 7.7 Hz), 7.09 (1H, d, J 7.7 Hz), 5.11 (2H, s), 3.89 (6H, s),
3.75 (3H, s), 3.12 (3H, s), 2.87 (3H, s), 2.32 (3H, s), 2.28 (3H, s). ESI MS
calculated for C27H31N2O7S [M þ H]þ: 527.2, found: 526.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] propionamide (12). Propionoyl chloride was used
and it was stirred at room temperature overnight. White solid,
melting point 168e170 C, yield 88%: 1H NMR (400MHz, DMSO d6)
d 10.00 (1H, s), 7.58 (1H, s), 7.28 (1H, s), 7.23 (1H, d, J 8.5 Hz),
7.16(1H, s), 7.14(1H, d, J 7.6 Hz), 7.08 (1H, d, J 7.6 Hz), 5.06 (2H,
s), 3.08 (3H, s), 2.84 (3H, s), 2.36 (2H, dd, J 7.5, 6.4 Hz), 2.30 (3H, s),
2.27 (3H, s), 1.10 (3H, dd, J 7.5, 7.6 Hz). ESI MS calculated for
C20H25N2O4S [M þ H]þ: 389.2, found: 388.9.
Hexadecanoic acid [3 (2,5 dimethyl benzyloxy) 4 (meth
anesulfonyl methyl amino) phenyl] amide (13). Hexadecanoyl chlo
ride was used and it was stirred at room temperature overnight.
White solid, melting point 134e140 C(decomposed), yield 98%: 1H
NMR (400 MHz, DMSO d6) d 10.03 (1H, s), 7.59 (1H, s), 7.28 (1H, s),
7.20 (4H, m), 5.06 (2H, s), 3.08 (3H, s), 2.84 (3H, s), 2.30 (3H, s), 2.27
(3H, s), 1.58 (2H, br), 1.23 (26H, br), 0.87 (3H, dd, J 5.1, 6.6 Hz).
2,4 Dichloro N [3 (2,5 dimethyl benzyloxy) 4 (meth
anesulfonyl methyl amino) phenyl] benzamide (14). 2,4 Dichloro
benzoyl chloride was used and it was stirred at room temperature
overnight. White solid, melting point 163e166 C, yield 80%: 1H
NMR (400 MHz, DMSO d6) d 10.68 (1H, s), 7.79 (1H, s), 7.61 (1H, s),
7.64 (1H, d, J 8.2 Hz), 7.59 (1H, d, J 8.4 Hz), 7.29 (3H, br), 7.14(1H,
d, J 7.4 Hz), 7.08 (1H, d, J 7.4 Hz), 5.09 (2H, s), 3.12 (3H, s), 2.87
(3H, s), 2.31 (3H, s), 2.27 (3H, s). ESI MS calculated for
C24H23Cl2N2O4S [M þ H]þ: 505.1, found: 504.8.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 3 triﬂuoromethyl benzamide (15). 3 Triﬂuorome
thyl benzoyl chloride was used and it was stirred at room
temperature overnight. White solid, melting point 179e181 C,
yield 93%: 1H NMR (400 MHz, DMSO d6) d 10.61 (1H, s), 8.30 (2H,
m), 8.00 (1H, d, J 7.6 Hz), 7.81 (2H, m), 7.44 (1H, d, J 8.5 Hz),
7.32(1H, s), 7.32 (1H, d, J 8.4 Hz), 7.15(1H, d, J 7.6 Hz), 7.09 (1H, d,
J 7.6 Hz), 5.11 (2H, s), 3.12 (3H, s), 2.87 (3H, s), 2.32 (3H, s), 2.28
(3H, s). ESI MS calculated for C25H24F3N2O4S [M þ H]þ: 505.1,
found: 504.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 3,4 dimethoxy benzamide (16). 3,4 Dimethoxy
benzoyl chloride was used and it was stirred at room temperature
overnight. White solid, melting point 184e186 C, yield 93%: IR
n 3352 (NeH), 1649 (C]O), 1599, 1505 (aromatic C]C). 1H NMR
(400MHz, CDCl3) d 8.025 (2H,m), 7.510 (1H, J 2 Hz), 7.434 (1H, dd,
J 8.4, 2 Hz), 7.309 (1H, J 8.8 Hz), 7.162 (1H, s), 7.109 (2H, m),
6.919 (1H, d, J 8.4 Hz), 6.832 (1H, dd, J 2, 8.4 Hz), 5.067 (2H, s),
3.957 (3H, s), 3.952 (3H, s), 3.195 (3H, s), 2.707 (3H, s), 2.335 (3H, s),
2.320 (3H, s). 13C NMR (100 MHz, DMSO d6) d 164.933, 155.138,
151.682, 148.242, 140.278, 134.709, 134.099, 133.130, 130.865,
130.010, 129.194, 128.683, 126.616, 124.457, 120.948, 112.312,
110.955, 110.749, 105.355, 68.114, 55.588, 55.527, 37.608, 37.516,
20.520, 17.873. ESI MS calculated for C26H29N2O6S[M þ H]þ: 497.2,
found: 496.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] (3,4 dimethoxyphenyl) acetamide (17). (3,4 Dime
thoxy phenyl) acetyl chloride was used and it was stirred at
room temperature overnight. White solid, melting point
149e152 C, yield 95%: 1H NMR (400 MHz, CDCl3) d 7.844 (1H, d,
J 2.4 Hz), 7.240 (2H, m), 7.141 (1H, s), 7.103 (2H, m), 6.893 (2H, m),
6.825 (1H, d, J 1.6 Hz), 6.555 (1H, dd, J 2.4, 8.4 Hz), 5.029 (2H, s),
3.907 (3H, s), 3.898 (3H, s), 3.696 (2H, s), 3.157 (3H, s) 2.683 (3H, s),
2.322 (3H, s), 2.312 (3H, s). ESI MS calculated for C27H31N2O6S
[M þ H]þ: 511.2, found: 510.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 methoxy benzamide (18). 4 Methoxy benzoyl
chloride was used and it was stirred at room temperature over
night. White solid, melting point 175e178 C, yield 96%: IR n 3345
(NeH),1649 (C]O),1602,1506 (aromatic C]C). 1H NMR (400MHz,
CDCl3) d 8.022 (1H, d, J 2.4 Hz), 7.864 (3H, m), 7.330 (1H, d,
J 8.4 Hz), 7.175 (1H, s), 7.113 (2H, m), 6.995 (2H, m), 6.823 (1H, dd,
J 2.4, 8.4 Hz), 5.086 (2H, s), 3.886 (3H, s), 3.198 (3H, s), 2.712 (3H,
s), 2.345 (3H, s), 2.325 (3H, s). 13C NMR (100 MHz, DMSO d6)
d 164.887, 161.920, 155.107, 140.324, 134.694, 134.091, 133.107,
130.857, 129.995, 129.552, 129.171, 128.660, 126.600, 124.380,
113.541, 112.190, 105.264, 68.083, 55.351, 37.593, 37.509, 20.513,
17.866. ESI MS calculated for C25H27N2O5S [M þ H]þ: 467.2, found:
466.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 2 methoxy benzamide (19). 2 Methoxy benzoyl
chloride was used and it was stirred at room temperature over
night. White solid, melting point 147e149 C, yield 97%: 1H NMR
(400 MHz, CDCl3) d 9.932 (1H, s), 8.283 (1H, dd, J 2, 8 Hz), 8.202
(1H, d, J 2.4 Hz), 7.535 (1H, m), 7.342 (1H, d, J 8.4 Hz), 7.106 (5H,
m), 6.759 (1H, dd, J 2, 8.4 Hz), 5.119 (2H, s), 4.079 (3H, s), 3.201
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(3H, s), 2.706 (3H, s), 2.361 (3H, s), 2.329 (3H, s). ESI MS calculated
for C25H27N2O5S [M þ H]þ: 467.2, found: 466.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 3 methoxy benzamide (20). 3 Methoxy benzoyl
chloride was used and it was stirred at room temperature over
night. White solid, melting point 143e144 C, yield 91%: 1H NMR
(400MHz, CDCl3) d 8.021 (1H, d, J 2.4 Hz), 7.938 (1H, s), 7.445 (1H,
m), 7.406 (2H, m), 7344 (1H, d, J 8.4 Hz), 7.177 (1H, s), 7.121 (3H,
m), 6.848 (1H, dd, J 2.4, 8.4 Hz), 5.093 (2H, s), 3.885 (3H, s), 3.201
(3H, s), 2.714 (3H, s), 2.349 (3H, s), 2.327 (3H, s). ESI MS calculated
for C25H27N2O5S [M þ H]þ: 467.2, found: 466.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 3 methoxy 2,4,5 triﬂuorobenzamide (21). 3 Meth
oxy 2,4,5 triﬂuorobenzoyl chloride was used and it was stirred at
room temperature overnight. White solid, melting point
166e169 C, yield 98%: 1H NMR (400 MHz, CDCl3) d 8.381 (1H, d,
J 14.8 Hz), 7.927 (1H, s), 7.680 (1H, m), 7.362 (1H, d, J 8.4 Hz),
7.180 (1H, s), 7.115 (2H, m), 6.880 (1H, d, J 8.4 Hz), 5.094 (2H, s),
4.106 (3H, s), 3.199 (3H, s), 2.719 (3H, s), 2.358 (3H, s), 2.328 (3H, s).
ESI MS calculated for C25H24F3N2O5S [Mþ H]þ: 521.1, found: 520.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 2 ethyl butyramide (22). 2 Ethyl butyryl chloride
was used and it was stirred at room temperature overnight. White
solid, melting point 151e154 C, yield 96%: 1H NMR (400 MHz,
CDCl3) d 8.049 (1H, d, J 2.4 Hz), 7.296 (1H, s), 7.275 (1H, s), 7.157
(1H, s), 7.108 (2H, m), 6.673 (1H, dd, J 2.4, 8.8 Hz), 5.064 (2H, s),
3.172 (3H, s), 2.691(3H, s), 2.339 (3H, s), 2.318 (3H, s), 2.08 (1H, m),
1.70 (4H, m), 0.970 (6H, t, J 7.6 Hz). ESI MS calculated for
C23H31N2O4S [M þ H]þ: 431.2, found: 430.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] cyclopentanecarboxamide (23). Cyclopentane carb
onyl chloride was used and it was stirred at room temperature
overnight. White solid, melting point 170e172 C, yield 93%: 1H
NMR (400 MHz, CDCl3) d 7.998 (1H, d, J 2 Hz), 7.357 (1H, s), 7.265
(1H, d, J 8.4 Hz), 7.149 (1H, s), 7.106 (2H, m), 6.641 (1H, dd, J 2.4,
8.4 Hz), 5.045 (2H, s), 3.169 (3H, s), 2.703 (1H, m), 2.690 (3H, s),
2.327 (3H, s), 2.318 (3H, s), 1.921 (4H, m), 1.80 (2H, m), 1.641(2H, m).
ESI MS calculated for C23H29N2O4S [M þ H]þ: 429.2, found: 428.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 2 phenyl acetamide (24). Phenylacetyl chloridewas
used and it was stirred at room temperature overnight. White solid,
melting point 185e186 C, yield 99%: 1H NMR (400 MHz, CDCl3)
d7.867 (1H, d, J 2.4Hz), 7.399 (5H,m), 7.239 (1H, d, J 8.4Hz), 7.187
(1H, s), 7.102 (3H, m), 6.535 (1H, dd, J 3, 9 Hz), 5.026 (2H, s), 3.757
(2H, s), 3.156 (3H, s), 2.679 (3H, s), 2.320 (3H, s), 2.312 (3H, s). ESI MS
calculated for C25H27N2O4S [M þ H]þ: 451.2, found: 450.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 1 naphthalenecarboxyamide (25). 1 Naphthoyl
chloride was used and it was stirred at room temperature over
night. White solid, melting point 164e168 C, yield 83%: 1H NMR
(400 MHz, CDCl3) d 8.350 (1H, d, J 8 Hz), 8.105 (1H, s), 7.992 (1H,
d, J 8.4 Hz), 7.921 (1H, m), 7.865 (1H, s), 7.741 (1H, d, J 6.4 Hz),
7.543 (3H, m), 7.345 (1H, d, J 8.4 Hz), 7.199 (1H, s), 7.116 (2H, m),
6.845 (1H, dd, J 2, 8.4 Hz), 5.129 (2H, s), 3.208 (3H, s), 2.711 (3H, s),
2.365 (3H, s), 2.336 (3H, s). ESI MS calculated for C28H29N2O4S
[M þ H]þ: 489.2, found: 489.1.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 3,5 bis(triﬂuoro methyl)benzamide (26). 3,5 Bis
(triﬂuoro methyl)benzoyl chloride was used and it was stirred at
room temperature overnight. White solid, melting point
191e192 C, yield 93%: 1H NMR (400 MHz, CDCl3) d 8.348 (3H, s),
8.067 (1H, s), 7.892 (1H, s), 7.289 (1H, d, J 10.8 Hz), 7.173 (1H, s),
7.108 (2H, m), 6.908 (1H, d, J 8.4 Hz), 5.051 (2H, s), 3.193(3H, s),
2.754 (3H, s), 2.342 (3H, s), 2.309 (3H, s). ESI MS calculated for
C26H23F6N2O4S [M þ H]þ: 573.1, found: 572.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 3 bromobenzamide (27). 3 Bromobenzoyl chloride
was used and it was stirred at room temperature overnight. White
solid, melting point 176e178 C, yield 99%: 1H NMR (400 MHz,
CDCl3) d 8.022 (2H, m), 7.947 (1H, d, J 2.4 Hz)), 7.810 (1H, d,
J 8 Hz), 7.698 (1H, d, J 8 Hz), 7.404 (1H, t, J 8 Hz), 7.320 (1H, d,
J 8.4 Hz), 7.172 (1H, s), 7.114 (2H, m), 6.867 (1H, dd, J 2.4, 8.4 Hz),
5.072 (2H, s), 3.199 (3H, s), 2.726 (3H, s), 2.343 (3H, s), 2.322 (3H, s).
ESI MS calculated for C24H24BrN2O4S [M þ H]þ: 515.1, found: 514.8.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 chlorobenzamide (28). 4 Chloro benzoyl chlo
ride was used and it was stirred at room temperature overnight.
White solid, melting point 171e174 C, yield 99%: 1H NMR
(400MHz, CDCl3) d 7.967 (1H, d, J 2.4 Hz), 7.951 (1H, s), 7.838 (2H,
m), 7.491 (2H, m), 7.335 (1H, d, J 8.4 Hz), 7.176 (1H, s), 7.111 (2H,
m), 6.850 (1H, dd, J 2.4, 8.4 Hz), 5.084 (2H, s), 3.204 (3H, s), 2.725
(3H, s), 2.348 (3H, s), 2.326 (3H, s). ESI MS calculated for
C24H24ClN2O4S [M þ H]þ: 471.1, found: 470.8.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 iodobenzamide (29). 4 Iodo benzoyl chloride
was used and it was stirred at room temperature overnight. White
solid, melting point 207e209 C, yield 96%: IR n 3308 (NeH),1653
(C]O), 1594, 1518 (aromatic C]C). 1H NMR (400 MHz, DMSO d6)
d 10.408 (1H, s), 7.939 (2H, m), 7.748 (3H, m), 7.398 (1H, dd, J 2.4,
8.8 Hz), 7.291 (2H, m), 7.124 (2H, m), 5.090 (2H, s), 3.105(3H, s),
2.858 (3H, s), 2.311 (3H, s), 2.270 (3H, s). 13C NMR (100MHz, DMSO
d6) d 164.811, 155.130, 139.912, 137.204, 134.686, 134.046, 133.954,
133.092, 130.926, 129.995, 129.514, 129.133, 128.660, 124.762,
112.328, 105.386, 99.474, 68.106, 37.615, 37.486, 20.513, 17.858. ESI
MS calculated for C24H24IN2O4S [M þ H]þ: 563.1, found: 562.8.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 methylsulfanyl benzamide (30). 4 Methylsulfanyl
benzoyl chloride was used and it was stirred at room temperature
overnight.White solid,melting point 195e197 C, yield 92%: 1HNMR
(400 MHz, CDCl3) d 8.017 (1H, d, J 2.4 Hz), 7.868 (1H, s), 7.799 (2H,
m), 7.327 (3H, m), 7.177 (1H, s), 7.116 (2H, m), 6.834 (1H, dd, J 2,
8.4 Hz), 5.093 (2H, s), 3.200 (3H, s), 2.715 (3H, s), 2.543 (3H, s), 2.348
(3H, s), 2.326 (3H, s). ESI MS calculated for C25H27N2O4S2 [M þ H]þ:
483.1, found: 483.0.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 dimethylamino benzamide (31). 4 Dimethylamino
benzoyl chloride was used and it was stirred at room temperature
overnight. White solid, melting point 171e172 C, yield 66%: 1H NMR
(400MHz, CDCl3) d 8.086 (1H, d, J 2.4 Hz), 7.823 (1H, s), 7.789 (2H, d,
J 9.2 Hz), 7.321 (1H, d, J 8.4 Hz), 7.174 (1H, s), 7.110 (2H, m), 6.790
(1H, dd, J 2, 8.4 Hz), 6.720 (2H, d, J 9.2 Hz), 5.089 (2H, s), 3.194 (3H,
s), 3.064 (6H, s), 2.703 (3H, s), 2.343 (3H, s), 2.324 (3H, s). ESI MS
calculated for C26H30N3O4S [M þ H]þ: 480.2, found: 479.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 ethoxy benzamide (32). 4 Ethoxy benzoyl chlo
ride was used and it was stirred at room temperature overnight.
White solid, melting point 184e185 C, yield 70%: 1H NMR
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(400 MHz, CDCl3) d 8.014 (1H, d, J 2 Hz), 7.925 (1H, s), 7.847 (2H,
m), 7.316 (1H, d, J 8.4 Hz), 7.168 (1H, s), 7.110 (2H, m), 6.972 (2H,
m), 6.822 (1H, dd, J 2.4, 8.4 Hz), 5.074 (2H, s), 4.111 (2H, q,
J 7.2 Hz), 3.195 (3H, s), 2.708 (3H, s), 2.340 (3H, s), 2.320 (3H, s),
1.455 (3H, t, J 7.2 Hz). ESI MS calculated for C26H29N2O5S
[M þ H]þ: 481.2, found: 480.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 ethyl benzamide (33). 4 Ethyl benzoyl chloride
was used and it was stirred at room temperature overnight. Pale
yellow solid, melting point 178e181 C, yield 64%: 1H NMR
(400MHz, CDCl3) d 8.038 (1H, d, J 2.4 Hz), 7.987 (1H, s), 7.814 (2H,
m), 7.327 (3H, m), 7.173 (1H, s), 7.112 (2H, m), 6.834 (1H, dd, J 2.4,
8.4 Hz), 5.083 (2H, s), 3.197 (3H, s), 2.733 (2H, q, J 7.6 Hz), 2.708
(3H, s), 2.343 (3H, s), 2.324 (3H, s), 1.276 (3H, t, J 7.6 Hz). ESI MS
calculated for C26H29N2O4S[M þ H]þ: 465.2, found: 464.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 triﬂuoromethyl benzamide (34). 4 Triﬂuorome
thyl benzoyl chloride was used and it was stirred at room
temperature overnight. White solid, melting point 215e218 C,
yield 84%: 1H NMR (400 MHz, DMSO d6) d 10.590 (1H, s), 8.157 (2H,
d, J 8 Hz), 7.941 (2H, d, J 8 Hz), 7.753 (1H, d, J 2.4 Hz), 7.419
(1H, dd, J 2.4, 8.8 Hz), 7.307 (2H, m), 7.129 (2H, m), 5.107 (2H, s),
3.116 (3H, s), 2.871 (3H, s), 2.319 (3H, s), 2.275 (3H, s). ESI MS
calculated for C25H24F3N2O4S [M þ H]þ: 505.1, found: 504.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 trifuoromethoxy benzamide (35). 4 Triﬂuorome
thoxy benzoyl chloride was used and it was stirred at room
temperature overnight. White solid, melting point 194e197 C,
yield 79%: 1H NMR (400MHz, CDCl3) d 7.954 (4H, m), 7.350 (3H, m),
7.177 (1H, s), 7.117 (2H, m), 7.848 (1H, dd, J 2.4, 8.4 Hz), 5.088 (2H,
s), 3.204 (3H, s), 2.724 (3H, s), 2.349 (3H, s), 2.324 (3H, s). ESI MS
calculated for C25H24F3N2O5S [M þ H]þ: 521.1, found: 520.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] 4 methyl benzamide (36). 4 Methyl benzoyl chlo
ride was used and it was stirred at room temperature overnight.
White solid, melting point 170e173 C, yield 69%: 1H NMR
(400 MHz, CDCl3) d 8.032 (1H, d, J 2 Hz), 7.956 (1H, s), 7.786 (2H,
m), 7.339 (1H, s), 7.309 (2H, d, J 7.6 Hz), 7.175 (1H, s), 7.113 (2H, m),
6.834 (1H, dd, J 2, 8.4 Hz), 5.084 (2H, s), 3.198 (3H, s), 2.710 (3H, s),
2.438 (3H, s), 2.344 (3H, s), 2.324 (3H, s). ESI MS calculated for
C25H27N2O4S [M þ H]þ: 451.2, found: 450.9.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] furan 2 carboxamide (37). 2 Furoyl chloride was
used and it was stirred at room temperature overnight. White solid,
melting point 156e157 C, yield 66%: 1H NMR (400 MHz, CDCl3)
d 8.159 (1H, s), 8.004 (1H, d, J 2.4 Hz), 7.551 (1H, m), 7.352 (1H, d,
J 8.4 Hz), 7.268 (1H, m), 7.180 (1H, s), 7.119 (2H, m), 6.875 (1H, dd,
J 2.4, 8.8 Hz), 6.595 (1H, dd, J 2, 3.6 Hz), 5.091 (2H, s), 3.202 (3H,
s), 2.720 (3H, s), 2.351 (3H, s), 2.328 (3H, s). ESI MS calculated for
C22H23N2O5S [M þ H]þ: 427.1, found: 426.8.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] thiophene 2 carboxamide (38). 2 Thiophene carbonyl
chloride was used and it was stirred at room temperature overnight.
White solid, melting point 163e164 C, yield 72%: 1HNMR (400MHz,
CDCl3) d 7.986 (1H, d, J 2.4 Hz), 7.877 (1H, s), 7.668 (1H, dd, J 1.2,
3.6 Hz), 7.589 (1H, dd, J 1.2, 5.2 Hz), 7.323 (1H, d, J 8.4 Hz), 7.144
(4H, m), 6.816 (1H, dd, J 2.4, 8.8 Hz), 5.072 (2H, s), 3.197 (3H, s),
2.718 (3H, s), 2.341(3H, s), 2.324 (3H, s). ESI MS calculated for
C22H23N2O4S2[M þ H]þ: 443.1, found: 442.8.
N [3 (2,5 dimethyl benzyloxy) 4 (methanesulfonyl methyl
amino) phenyl] isoxazole 5 carboxamide (39). Isoxazole 5 carbonyl
chloride was used and it was stirred at room temperature over
night. White solid, melting point 130e138 C(decomposed), yield
99%: 1HNMR (400MHz, CDCl3) d 8.418 (1H, d, J 2Hz), 8.360 (1H, s),
7.849 (1H, dd, J 2.4 Hz), 7.391 (1H, d, J 8.4 Hz), 7.181 (1H, s), 7.126
(2H, m), 7.060 (1H, d, J 2 Hz), 7.005 (1H, dd, J 2.4, 8.4 Hz), 5.095
(2H, s), 3.211 (3H, s), 2.741 (3H, s), 2.357 (3H, s), 2.329 (3H, s). ESI MS
calculated for C21H22N3O5S [M þ H]þ: 428.1, found: 427.8.
Pharmacological studies
Cell culture
SKBR 3, HT29 cells were obtained fromATCC (Rockville, MD). All
cells were maintained in RPMI1640 medium supplemented with
10% fetal bovine serum (FBS), 2 mmol/L L Glutamine, 1 mmol/L
sodium pyruvate, 100 U/mL penicillin streptomycin. FBS was heat
inactivated for 30min in a 56 Cwater bath before use. Cell cultures
were grown at 37 C, in a humidiﬁed atmosphere of 5% CO2 in
a Hereaus CO2 incubator.
Cell viability analysis
The effect of nimesulides derivatives on SKBR 3 and HT29 cell
viability was assessed by using the 3 (4,5 dimethylthiazol 2 yl)
2,5 diphenyl 2H tetrazolium bromide assay in six replicates. Cells
were grown in RPMI1640 medium in 96 well, ﬂat bottomed plates
for 24 h, and were exposed to various concentrations of JCC76
derivatives dissolved in DMSO (ﬁnal concentration 0.1%) in media
for 48 h. Controls received DMSO vehicle at a concentration equal to
that in drug treated cells. The medium was removed, replaced by
200 ml of 0.5 mg/mL of 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyl
2H tetrazolium bromide in freshmedia, and cells were incubated in
the CO2 incubator at 37 C for 2 h. Supernatants were removed
from the wells, and the reduced 3 (4,5 dimethylthiazol 2 yl) 2,5
diphenyl 2H tetrazolium bromide dye was solubilized in 200 ml/
well DMSO. Absorbance at 570 nm was determined on a plate
reader.
Flow cytometry analysis
For all the assays, cells were treated for the indicated time. To
analyze the cell cycle proﬁle, treated cells were ﬁxed overnightwith
70% EtOH at 20 C and stained with propidium iodide buffer
[38 mM sodium citrate (pH 7.5), 69 mM propidium iodide, and
120 mg/mL RNase A]. Samples were mixed gently and incubated at
room temperature in the dark for 15 min. Immediately before
analysis byﬂowcytometry, 400 mL binding bufferwas added to each
sample. A total of 1.2  104 cells were acquired for each sample and
a maximum of 1 104 cells within the gated region were analyzed.
In vivo xenograft studies
Five to six week old BALB/c nu/nu, athymic, mice were
purchased from Charles River Laboratories, Inc. (Wilmington, MA).
Subconﬂuent HT29 cells were harvested from monolayer culture
and resuspended in an equal volume of Matrigel (BD Biosciences,
San Jose, CA) to a ﬁnal concentration of 1 107/0.2 mL. At 10 weeks
of age, each animal received s.c. inoculations in two sites per ﬂank
with 200 mL of HT29 cell suspension. Six animals were randomly
grouped into two. Tumors were measured twice weekly with
calipers, and tumor volume was calculated by the following
formula: (width)2  length/2. Treatments began when the tumors
reached a measurable size (w200 mm3). Treated group was intra
peritoneal administrated 5 mg/kg/d of CSUOH0901 ﬁve times
aweek (1%DMSO, sesame oil as vehicle). The control group received
the vehicle treatment. Body weights were monitored weekly as an
indicator of the animals’ overall health. After three weeks of
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treatment, the mice were euthanized and the tumors were
removed, weighed.
Preparation of calibration standards and quality controls
(QC) samples
The stock standard solutions of CSUOH0901 were prepared by
dissolving in DMSO it at 1 mg/mL and stored at 20 C. One set of
CSUOH0901working solutions at 3,10, 20,100, 200 and1000ng/mL,
prepared by serial diluting stock solution with 50% acetonitrile in
water, was used for calibration standards. Another set of JCC76
working solutions at 3, 9, 90, and 900 ng/mLwasmade in the similar
way and used for QC samples. All of the working solutions were
freshly prepared before use. Calibration standardswere prepared by
spiking 5 mL different CSUOH0901 working solutions into 50 mL
blank rat plasma to give theﬁnal concentrationof CSUOH0901at 0.3,
1, 2,10, 2 and100ng/mL. TheQC sampleswereprepared in sameway
as the calibration standards at four different levels of 0.3, 0.9, 9 and
90 ng/mL, representing lower limit of quantitation (LLOQ), low QC
(LQC), middle QC (MQC) and high QC (HQC) of CSUOH0901 in
plasma. All of the calibration standards andQC sampleswere further
treated in the same preparation procedure.
Pharmacokinetic study
Male SpragueeDawley rats (each weight 300e350 g) were
purchased from Charles River Laboratories International (Spencer
ville, OH, USA). Animals were housed in a 12 h light/dark cycle room
with free access to food and water for at least 7 days to adapt the
environment. All the animal experiment procedures were per
formed under the guideline approved by Institutional Animal Care
and Use Committee at Cleveland State University.
Before the intraperitoneal administration of CSUOH0901 at
a single dose of 20 mg/kg (PBS with 01% Tween80, 20% DMSO as
vehicle), animals were fasted overnight but with free access of
water. Blood samples of 150 mL each were collected from the
saphenous veins and femoral veins into heparized tubes at 0 h
(before drug administration) and at 0.25, 0.5, 1, 2, 4, 8 and 24 h after
dosing. The blood samples were centrifuged immediately at
10,000 rpm for 5 min in room temperature. The plasma samples
were separated and store at e20 C until analysis.
Plasma concentrations of CSUOH0901 were determined by an
LCeMS/MS method developed and validated for this study. The LC
MS/MS method consisted of a Shimazu HPLC system ((Shimazu,
Tokyo, Japan) and an AB Sciex QTrap 5500 mass spectrometer
equipped with an electrospray ionization source (ABI Sciex, Tor
onto, Canada). The chromatographic separationwas achieved using
a C 18 column (2.0 mm  150 mm, 5 mm) together with 0.5 mM
ammonium formate in 90% methanol for isocratic elution. The
eluates were detected using multiple reaction monitoring (MRM)
mode for CSUOH0901 (m/z 483.3 to 404.3) and the internal stan
dard JCC76 (m/z 445 to 366.3). The liquideliquid extraction method
using themixture of tert butyl methyl ether and n hexane (1:1, v/v)
was optimized for plasma sample pretreatment. This analytical
method was validated over the concentration range of 0.1e100 ng/
mL (r2  0.999). The intra and inter assay variability (% coefﬁcient
of variation) and mean bias (% relative error) were evaluated and
less than 15%. Plasma quantiﬁed above the highest concentration of
the standard curvewere diluted with blank plasma and reanalyzed.
The concentration of CSUOH0901 in rat plasma versus time
proﬁles were analyzed to estimate pharmacokinetics parameters
using WinNonlin software version 5.2 (Pharsight Corporation,
Mountain View, CA, USA). The estimated pharmacokinetic param
eters including the terminal phase elimination half life (T1/2), and
the area under the plasma concentration time curve (AUC) from
time 0 to time of the last measurable concentration (AUC(0-t)), the
volume of distribution (Vz/F), the total body clearance (Cl/F), and the
mean residence time (MRT) from time 0 to time of the last
measurable concentration (MRT(0-t)) were determined.
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